论文部分内容阅读
目的探讨β-连接素(β-catenin)在不同亚型乳腺癌中的表达及其临床意义。方法应用组织芯片、免疫组织化学方法检测38例三阴性乳腺癌、131例非三阴性乳腺癌和10例正常乳腺组织β-catenin的表达情况。结果正常乳腺组织β-catenin仅细胞膜表达;乳腺癌组织β-catenin细胞膜、细胞浆和细胞核同时表达。三阴性乳腺癌β-catenin异常表达率为78.9%,高于非三阴性乳腺癌(60.3%)(P<0.05)。β-catenin异常表达与淋巴结转移、组织学分级、临床分期、Ki67状态及预后相关(P<0.05)。结论β-catenin在乳腺癌的发生发展中起重要作用,有望成为判断乳腺癌生物学行为和预后以及靶向治疗的新指标。
Objective To investigate the expression and clinical significance of β-catenin in different subtypes of breast cancer. Methods The expression of β-catenin in 38 cases of triple negative breast cancer, 131 cases of non-triple negative breast cancer and 10 cases of normal breast tissue was detected by tissue microarray and immunohistochemistry. Results The expression of β-catenin in normal breast tissue was only in the cell membrane. The β-catenin membrane in cytoplasm and nucleus of breast cancer tissues were also expressed. The abnormal expression of β-catenin in triple negative breast cancer was 78.9%, higher than that in non-triple negative breast cancer (60.3%) (P <0.05). Aberrant expression of β-catenin correlated with lymph node metastasis, histological grade, clinical stage, Ki67 status and prognosis (P <0.05). Conclusion β-catenin plays an important role in the occurrence and development of breast cancer and is expected to become a new indicator to judge the biological behavior and prognosis of breast cancer and targeted therapy.